Escitalopram and enhancement of cognitive recovery following stroke

Archives of General Psychiatry

Volumn 67, Issue 2, 2010, Pages 187-196

  Jorge, Ricardo E ^a   Acion, Laura ^a,b   Moser, David ^a   Adams Jr , Harold P ^a   Robinson, Robert G ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MEMORY; MORNING DOSAGE; NEUROPSYCHOLOGICAL TEST; PROBLEM SOLVING; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STROKE;

AGED; CITALOPRAM; COGNITION DISORDERS; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PROBLEM SOLVING; SEROTONIN UPTAKE INHIBITORS; STROKE;

EID: 76149097866     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2009.185     Document Type: Article

References (85)

1. Mackay J, et al. The Atlas of Heart Disease and Stroke. Geneva, Switzerland: World Health Organization; 2004.
2. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-e146.
3. Klijn CJ, Hankey GJ; American Stroke Association and European Stroke Initiative. Management of acute ischaemic stroke: new guidelines from the American Stroke Association and European Stroke Initiative. Lancet Neurol. 2003;2(11): 698-701.
4. Norrving B, Adams RJ. Organized stroke care. Stroke. 2006;37(2):326-328.
5. Leira EC, Adams HP Jr. Management of acute ischemic stroke. Clin Geriatr Med. 1999;15(4):701-720.
6. Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-1587.
7. Caplan LR. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1999;341(16):1240-1241.
8. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, Freo U, Piron L, Battistin L. Effects of fluoxetine and maprotiline on functional recovery in post-stroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996; 27(7):1211-1214.
9. Stroemer RP, Kent TA, Hulsebosch CE. Enhanced neocortical neural sprouting, synaptogenesis, and behavioral recovery with D-amphetamine therapy after neocortical infarction in rats. Stroke. 1998;29(11):2381-2395.
10. Scheidtmann K. Advances in adjuvant pharmacotherapy for motor rehabilitation: effects of levodopa. Restor Neurol Neurosci. 2004;22(3-5):393-398.
11. Gladstone DJ, Danells CJ, Armesto A, Mcllroy WE, Staines WR, Graham SJ, Herrmann N, Szalai JP, Black SE; Subacute Therapy with Amphetamine and Rehabilitation for Stroke Study Investigators. Physiotherapy coupled with dextroamphetamine for rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial. Stroke. 2006;37(1):179-185.
12. Sonde L, Lokk J. Effects of amphetamine and/or L-dopa and physiotherapy after stroke: a blinded randomized study. Acta Neurol Scand. 2007;115(1):55-59.
13. Berthier ML, Green C, Higueras C, Fernández I, Hinojosa J, Martín MC. A randomized, placebo-controlled study of donepezil in poststroke aphasia. Neurology. 2006;67(9):1687-1689.
14. Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R; Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003; 34(10):2323-2330.
15. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359(9314): 1283-1290.
16. Goldstein LB. Effects of amphetamines and small related molecules on recovery after stroke in animals and man. Neuropharmacology. 2000;39(5):852-859.
17. Goldstein LB. Amphetamines and related drugs in motor recovery after stroke. Phys Med Rehabil Clin N Am. 2003;14(1)(suppl):S125-S134, x.
18. Román GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord. 2005;20(6):338-344.
19. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD; Donepezil 308 Study Group. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61(4):479-486.
20. Hachinski V. The 2005 Thomas Willis Lecture: stroke and vascular cognitive impairment: a transdisciplinary, translational and transactional approach. Stroke. 2007;38(4):1396.
21. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54(7):597-606.
22. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116-1127.
23. Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull. 2001;35(2):5-49.
24. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301(5634): 805-809.
25. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci. 2003;4(12):1002-1012.
26. Jacobs BL, Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry. 2000;5(3):262-269.
27. Radley JJ, Jacobs BL. 5-HT1A receptor antagonist administration decreases cell proliferation in the dentate gyrus. Brain Res. 2002;955(1-2):264- 267.
28. Banasr M, Hery M, Printemps R, Daszuta A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology. 2004;29(3):450-460.
29. Encinas JM, Vaahtokari A, Enikolopov G. Fluoxetine targets early progenitor cells in the adult brain. Proc Natl Acad Sci U S A. 2006;103(21):8233-8238.
30. Cramer SC. Repairing the human brain after stroke, II: restorative therapies. Ann Neurol. 2008;63(5):549-560.
31. Chemerinski E, Robinson RG, Kosier JT. Improved recovery in activities of daily living associated with remission of post-stroke depression. Stroke. 2001;32 (1):113-117.
32. Kimura M, Robinson RG, Kosier T. Treatment of cognitive impairment after post-stroke depression. Stroke. 2000;31(7):1482-1486.
33. Murata Y, Kimura M, Robinson RG. Does cognitive impairment cause post-stroke depression? Am J Geriatr Psychiatry. 2000;8(4):310-317.
34. Reding MJ, Orto LA, Winter SW, Fortuna IM, Di Ponte P, McDowell FH. Antidepressant therapy after stroke: a double-blind trial. Arch Neurol. 1986;43(8):763-765.
35. Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and post-stroke depression: a placebo controlled trial of antidepressants. Am J Psychiatry. 2003; 160(10):1823-1829.
36. Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, Fonzetti P, Hegel M, Arndt S. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA. 2008;299(20): 2391-2400.
37. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
38. De Renzi E, Vignolo LA. The token test: a sensitive test to detect receptive disturbances in aphasics. Brain. 1962;85:665-678.
39. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41.
40. Kunitz SC, Gross CR, Heyman A, Kase CS, Mohr JP, Price TR, Wolf PA. The pilot stroke data bank: Definition, design and data. Stroke. 1984;15(4):740-746.
41. Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitryptyline and placebo for major depression in primary care. BMJ. 1995;310(6977):441- 445.
42. Hegel MT, Barrett JE, Cornell JE, Oxman TE. Predictors of response to problem-solving treatment of depression in primary care. Behavior Therapy. 2002;33 (4):511-527.
43. Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM-IV (SCID). New York, NY: Biometric Research, New York State Psychiatric Institute; 1995.
44. Hamilton M. The assessment of anxiety state of rating. Br J Med Psychol. 1959; 32(1):50-55.
45. Forer S, Granger CV. Functional Independence Measure. Buffalo, NY: The Buffalo General Hospital State University of New York at Buffalo; 1987.
46. Hollingshead AB, Redlich FC. Social Class and Mental Illness: A Community Study. New York, NY: Wiley; 1958.
47. Randolph C. Repeatable Battery for the Assessment of Neuropsychological Status. New York, NY: The Psychological Corporation; 1998.
48. Army Individual Test Battery. Manual of Directions and Scoring. Washington, DC: War Department, Adjutant General's Office; 1994.
49. Benton AL, Hamsher K, Sivan AB. Multilingual Aphasia Examination. Iowa City, IA: AJA Associates; 1994.
50. Wechsler D. Wechsler Memory Scale. 3rd ed. San Antonio, TX: Harcourt Brace and Co; 1997.
51. Golden CJ. Stroop Color and Word Test. Chicago, IL: Stoelting; 1978.
52. Sugiura N. Further analysis of the data by Akaike's information criterion and the finite corrections. Comm Statist Theory Methods. 1978;7(1):13-26.
53. Schafer JL. Analysis of Incomplete Multivariate Data: Monographs on Statistics and Applied Probability 72. New York, NY: Chapman & Hall; 1997.
54. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: Wiley; 1987. Wiley Series in Probability and Mathematical Statistics.
55. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Wallin A, Dichgans M, Marler JR, Leblanc GG. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37(9):2220-2241.
56. King P, Song X, Rockwood K; CIVIC Investigators. Cognitive impairment of acute onset in the Consortium to Investigate Vascular Impairment of Cognition (CIVIC) study: occurrence, correlates, and outcomes. Am J Geriatr Psychiatry. 2006; 14(10):893-896.
57. Moorhouse P, Rockwood K. Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol. 2008;7(3):246-255.
58. Rockwood K, Brown M, Merry H, Sketris I, Fisk J; Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Societal costs of vascular cognitive impairment in older adults. Stroke. 2002;33(6):1605-1609.
59. Wolfson C, Wolfson DB, Asgharian M, M'Lan CE, Ostbye T, Rockwood K, Hogan DB; Clinical Progression of Dementia Study Group. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344(15):1111-1116.
60. Knopman DS, Rocca WA, Cha RH, Edland SD, Kokmen E. Survival study of vascular dementia in Rochester, Minnesota. Arch Neurol. 2003;60(1):85-90.
61. Bondareff W, Alpert M, Friedhoff AJ, Richter EM, Clary CM, Batzar E. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry. 2000;157(5):729-736.
62. Finkel SI, Richter EM, Clary CM. Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older. Int Psychogeriatr. 1999;11(1):85-99.
63. Lavretsky H, Roybal DJ, Ballmaier M, Toga AW, Kumar A. Antidepressant exposure may protect against decrement in frontal gray matter volumes in geriatric depression. J Clin Psychiatry. 2005;66(8):964-967.
64. Schmitt JA, Wingen M, Ramaekers JG, Evers EA, Riedel WJ. Serotonin and human cognitive performance. Curr Pharm Des. 2006;12(20):2473-2486.
65. Sambeth A, Riedel WJ, Tillie DE, Blokland A, Postma A, Schmitt JA. Memory impairments in humans after acute tryptophan depletion using a novel gelatin-based protein drink. J Psychopharmacol. 2009;23(1):56-64.
66. Harmer CJ, Bhagwagar Z, Cowen PJ, Goodwin GM. Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology (Berl). 2002;163(1):106-110.
67. Vandenbosch R, Borgs L, Beukelaers P, Belachew S, Moonen G, Nguyen L, Malgrange B. Adult neurogenesis and the diseased brain. Curr Med Chem. 2009; 16(6):652-666.
68. Macas J, Nern C, Plate KH, Momma S. Increased generation of neuronal progenitors after ischemic injury in the aged adult human forebrain. J Neurosci. 2006; 26(50):13114-13119.
69. Jin K, Wang X, Xie L, Mao XO, Zhu W, Wang Y, Shen J, Mao Y, Banwait S, Greenberg DA. Evidence for stroke-induced neurogenesis in the human brain. Proc Natl Acad Sci U S A. 2006;103(35):13198-13202.
70. Merens W, Willem Van der Does AJ, Spinhoven P. The effects of serotonin manipulations on emotional information processing and mood. J Affect Disord. 2007; 103(1-3):43-62.
71. Harrison BJ, Olver JS, Norman TR, Burrows GD, Wesnes KA, Nathan PJ. Selective effects of acute serotonin and catecholamine depletion on memory in healthy women. J Psychopharmacol. 2004;18(1):32-40.
72. Evers EA, Tillie DE, van der Veen FM, Lieben CK, Jolles J, Deutz NE, Schmitt JA. Effects of a novel method of acute tryptophan depletion on plasma tryptophan and cognitive performance in healthy volunteers. Psychopharmacology (Berl). 2005;178(1):92-99.
73. Riedel WJ, Klaassen T, Deutz NE, van Someren A, van Praag HM. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology (Berl). 1999;141(4):362-369.
74. Booij L, Merens W, Markus CR, Van der Does AJ. Diet rich in alpha-lactalbumin improves memory in unmedicated recovered depressed patients and matched controls. J Psychopharmacol. 2006;20(4):526-535.
75. Markus CR, Olivier B, de Haan EH. Whey protein rich in alpha-lactalbumin increases the ratio of plasma tryptophan to the sum of the other large neutral amino acids and improves cognitive performance in stress-vulnerable subjects. Am J Clin Nutr. 2002;75(6):1051-1056.
76. Robbins TW. Chemistry of the mind: neurochemical modulation of prefrontal cortical function. J Comp Neurol. 2005;493(1):140-146.
77. Rogers RD, Everitt BJ, Baldacchino A, Blackshaw AJ, Swainson R, Wynne K, Baker NB, Hunter J, Carthy T, Booker E, London M, Deakin JF, Sahakian BJ, Robbins TW. Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology. 1999;20(4):322-339.
78. Martinsson L, Hardemark H, Eksborg S. Amphetamines for improving recovery after stroke. Cochrane Database Syst Rev. 2007;(1):CD002090.
79. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6(9):782-792.
80. Feeney DM, De Smet AM, Rai S. Noradrenergic modulation of hemiplegia: facilitation and maintenance of recovery. Restor Neurol Neurosci. 2004;22(3-5): 175-190.
81. Ogren SO, Eriksson TM, Elvander-Tottie E, D'Addario C, Ekström JC, Svenningsson P, Meister B, Kehr J, Stiedl O. The role of 5-HT(1A) receptors in learning and memory. Behav Brain Res. 2008;195(1):54-77.
82. Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O'Leary OF, Castrén E, Maffei L. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science. 2008;320(5874):385-388.
83. Normann C, Schmitz D, Fürmaier A, Döing C, Bach M. Long-term plasticity of visually evoked potentials in humans is altered in major depression. Biol Psychiatry. 2007;62(5):373-380.
84. Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, Duan W. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol. 2008; 210(1):154-163.
85. Dupret D, Revest JM, Koehl M, Ichas F, De Giorgi F, Costet P, Abrous DN, Piazza PV. Spatial relational memory requires hippocampal adult neurogenesis. PLoS One. 2008;3(4):e1959.